Texas Attorney General Sues Tylenol Makers Over Autism Claims
“`html
Texas Sues tylenol Manufacturers Over Alleged Risks to Children’s Brain Progress
Table of Contents
Texas Attorney General Ken Paxton filed a lawsuit against Johnson & Johnson and Kenvue, the current and former manufacturers of Tylenol (acetaminophen), alleging they concealed potential dangers to children’s brain development. The suit follows a recent, unverified claim linking Tylenol use during pregnancy to autism.
The Lawsuit’s Core Claims
On February 29, 2024, texas Attorney General Ken Paxton announced a lawsuit against Johnson & Johnson and Kenvue, accusing them of knowingly endangering millions of children for profit. Paxton alleges the companies deliberately concealed data about potential neurological risks associated with acetaminophen exposure during fetal development (texas Attorney General Press Release,February 29,2024). The lawsuit claims the companies prioritized profits over public safety, failing to adequately warn consumers about these potential dangers.
According to Paxton’s statement,the companies “betrayed America by profiting off of pain and pushing pills regardless of the risks.” (Texas Attorney General Press Release, February 29, 2024). The suit does not specify the exact nature of the alleged neurological risks, but implies a connection to developmental issues.
The Context: Trump’s Claims and Existing Research
The lawsuit arrives shortly after former President Donald Trump amplified an unsubstantiated claim linking Tylenol use during pregnancy to autism. On January 26, 2024, Trump posted on social media alleging a connection between acetaminophen and autism (reuters, January 27, 2024). This claim has been widely debunked by medical experts.
While Trump’s claim lacks scientific backing, research *has* explored potential links between acetaminophen use during pregnancy and neurodevelopmental outcomes. A growing body of observational studies suggests a possible association between prenatal acetaminophen exposure and an increased risk of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), but these studies do not prove causation (National Library of Medicine, November 2022). Researchers emphasize that these are correlations, and other factors could be responsible for the observed associations.
It’s vital to note that acetaminophen remains widely recommended as a first-line pain reliever and fever reducer during pregnancy by many healthcare professionals, due to its relatively well-established safety profile compared to alternatives like ibuprofen or aspirin (American College of obstetricians and Gynecologists, accessed March 1, 2024).
Kenvue’s Response and Safety Data
Kenvue, the current manufacturer